Brazilian company Precisa Medicamentos, representing India’s Bharat Biotech, said it requested that the country’s health regulator, Anvisa, grant emergency authorisation to use the Covaxin Covid-19 vaccine.
In addition, it said Covaxin would be trialed in a Phase Three study in Brazil carried out in partnership with Sao Paulo’s Albert Einstein hospital.
